Daptomycin as an option for lock therapy: a systematic literature review

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49(1), 1–45 (2009).
  Medline CASGoogle Scholar
• 2. Almeida BM, Moreno DH, Vasconcelos V, Cacione DG. Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis. Cochrane Database Syst. Rev. 4(4), doi: 10.1002/14651858.CD013554.pub2 (2022) (Online).
  MedlineGoogle Scholar
• 3. Vassallo M, Dunais B, Roger PM. Antimicrobial lock therapy in central-line associated bloodstream infections: a systematic review. Infection 43(4), 389–398 (2015).
  Medline CASGoogle Scholar
• 4. Gompelman M, Paus C, Bond A et al. Comparing success rates in central venous catheter salvage for catheter-related bloodstream infections in adult patients on home parenteral nutrition: a systematic review and meta-analysis. Am. J. Clin. Nutr. 114(3), 1173–1188 (2021).
  MedlineGoogle Scholar
• 5. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55(3), 283–288 (2005).
  Medline CASGoogle Scholar
• 6. Shariati A, Dadashi M, Chegini Z et al. The global prevalence of daptomycin, tigecycline, quinupristin/dalfopristin, and linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob. Resist. Infect. Control 9(1), 56 (2020).
  MedlineGoogle Scholar
• 7. Dadashi M, Sharifian P, Bostanshirin N et al. The global prevalence of daptomycin, tigecycline, and linezolid-resistant Enterococcus faecalis and Enterococcus faecium strains from human clinical samples: a systematic review and meta-analysis. Front. Med. (Lausanne) 8, 720647 (2021).
  MedlineGoogle Scholar
• 8. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51(12), 4255–4260 (2007). • Study showing that daptomycin's mechanism of action is not dependent on cell division or active metabolism and bactericidal activity is retained against stationary and nondividing S. aureus cells, an important property relevant to biofilm-embedded bacteria.
  Medline CASGoogle Scholar
• 9. Bookstaver PB, Gerrald KR, Moran RR. Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis. Clin. Pharmacol. 2, 123–130 (2010). •• One of the few case series on daptomycin lock therapy.
  MedlineGoogle Scholar
• 10. Yen HW, Yang WC, Tarng DC et al. Daptomycin antibiotic lock therapy for hemodialysis patients with Gram-positive bloodstream infections following use of tunneled, cuffed hemodialysis catheters: retrospective single center analysis. Hemodial. Int. 20(2), 315–320 (2016). •• One of the few case series on daptomycin lock therapy.
  MedlineGoogle Scholar
• 11. Tatarelli P, Parisini A, Del Bono V, Mikulska M, Viscoli C. Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter. Infection 43(1), 107–109 (2015). •• One of the few case series on daptomycin lock therapy.
  Medline CASGoogle Scholar
• 12. Del Pozo JL, Rodil R, Aguinaga A et al. Daptomycin lock therapy for Gram-positive long-term catheter-related bloodstream infections. Int. J. Clin. Pract. 66(3), 305–308 (2012). •• One of the few case series on daptomycin lock therapy.
  MedlineGoogle Scholar
• 13. Vassallo M, Genillier PL, Dunais B et al. Short-course daptomycin lock and systemic therapy for catheter-related bloodstream infections: a retrospective cohort study in cancer patients with surgically implanted devices. J. Chemother. 29(4), 232–237 (2017). •• One of the few case series on daptomycin lock therapy, showing efficacy even with short-course (3 days) daptomycin lock therapy.
  Medline CASGoogle Scholar
• 14. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan – a web and mobile app for systematic reviews. Syst. Rev. 5(1), 210 (2016).
  MedlineGoogle Scholar
• 15. Van Praagh AD, Li T, Zhang S et al. Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections. Antimicrob. Agents Chemother. 55(9), 4081–4089 (2011).
  Medline CASGoogle Scholar
• 16. Bodega-Azuara J, Bellés-Medall MD, Edo-Peñarrocha J, Ferrando-Piqueres R, Perez-Alba A, Reque-Santivañez J. Vancomycin and daptomycin stability in heparin or sodium citrate lock solutions. J. Vasc. Access doi: 10.1177/11297298211045893 (.2021) (Epub Ahead of Print).
  MedlineGoogle Scholar
• 17. Bookstaver PB, Rokas KE, Norris LB, Edwards JM, Sherertz RJ. Stability and compatibility of antimicrobial lock solutions. Am. J. Health Syst. Pharm. 70(24), 2185–2198 (2013).
  Medline CASGoogle Scholar
• 18. Laplante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol. Dial. Transplant. 22(8), 2239–2246 (2007).
  Medline CASGoogle Scholar
• 19. Stewart PS, Davison WM, Steenbergen JN. Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob. Agents Chemother. 53(8), 3505–3507 (2009).
  Medline CASGoogle Scholar
• 20. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob. Agents Chemother. 54(10), 4329–4334 (2010).
  Medline CASGoogle Scholar
• 21. Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J. Antimicrob. Chemother. 67(11), 2682–2685 (2012).
  Medline CASGoogle Scholar
• 22. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51(5), 1656–1660 (2007).
  Medline CASGoogle Scholar
• 23. Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int. J. Antimicrob. Agents 33(4), 374–378 (2009).
  Medline CASGoogle Scholar
• 24. Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 57(6), 2726–2737 (2013).
  Medline CASGoogle Scholar
• 25. Estes R, Theusch J, Beck A, Pitrak D, Mullane KM. Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm. Antimicrob. Agents Chemother. 57(4), 1998–2000 (2013).
  Medline CASGoogle Scholar
• 26. Hogan S, Zapotoczna M, Stevens NT, Humphreys H, O'Gara JP, O'Neill E. In vitro approach for identification of the most effective agents for antimicrobial lock therapy in the treatment of intravascular catheter-related infections caused by Staphylococcus aureus. Antimicrob. Agents Chemother. 60(5), 2923–2931 (2016).
  Medline CASGoogle Scholar
• 27. Leite B, Gomes F, Teixeira P, Souza C, Pizzolitto E, Oliveira R. In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms. Curr. Microbiol. 63(3), 313–317 (2011).
  Medline CASGoogle Scholar
• 28. Ozturk B, Gunay N, Ertugrul BM, Sakarya S. Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative Staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model. Can. J. Microbiol. 62(9), 735–743 (2016).
  Medline CASGoogle Scholar
• 29. Presterl E, Hajdu S, Lassnigg AM, Hirschl AM, Holinka J, Graninger W. Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Antimicrob. Agents Chemother. 53(8), 3205–3210 (2009).
  Medline CASGoogle Scholar
• 30. Barber KE, Shammout Z, Smith JR, Kebriaei R, Morrisette T, Rybak MJ. Biofilm time–kill curves to assess the bactericidal activity of daptomycin combinations against biofilm-producing vancomycin-resistant Enterococcus faecium and faecalis. Antibiotics (Basel) 10(8), 897 (2021).
  Medline CASGoogle Scholar
• 31. Jahanbakhsh S, Singh NB, Yim J et al. Impact of daptomycin dose exposure alone or in combination with β-lactams or rifampin against vancomycin-resistant enterococci in an in vitro biofilm model. Antimicrob. Agents Chemother. 64(5), e020741-19 (2020).
  Google Scholar
• 32. Holmberg A, Rasmussen M. Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms. Int. J. Antimicrob. Agents 44(1), 78–80 (2014).
  Medline CASGoogle Scholar
• 33. Parra D, Peña-Monje A, Coronado-Álvarez NM, Hernández-Quero J, Parra-Ruiz J. In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. BMC Microbiol. 15, 245 (2015).
  MedlineGoogle Scholar
• 34. Aumeran C, Guyot P, Boisnoir M et al. Activity of ethanol and daptomycin lock on biofilm generated by an in vitro dynamic model using real subcutaneous injection ports. Eur. J. Clin. Microbiol. Infect. Dis. 32(2), 199–206 (2013).
  Medline CASGoogle Scholar
• 35. Meije Y, Almirante B, Del Pozo JL et al. Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection. J. Infect. 68(6), 548–552 (2014). •• Animal model showing potential superiority of higher-concentration (50mg/dl) daptomycin lock therapy.
  MedlineGoogle Scholar
• 36. Basas J, Palau M, Ratia C et al. High-dose daptomycin is effective as an antibiotic lock therapy in a rabbit model of Staphylococcus epidermidis catheter-related infection. Antimicrob. Agents Chemother. 62(2), e01777–17 (2018). •• Animal model showing potential superiority of higher-concentration (50mg/dl) daptomycin lock therapy.
  MedlineGoogle Scholar
• 37. Grau S, Gil MJ, Mateu-De Antonio J, Pera M, Marín-Casino M. Antibiotic-lock technique using daptomycin for subcutaneous injection ports in a patient on home parenteral nutrition. J. Infect. 59(4), 298–299 (2009).
  MedlineGoogle Scholar
• 38. Guimard T, Revest M, Arvieux C et al. Failure of antibiotic-lock technique using daptomycin for subcutaneous injection ports in a patient on home parenteral nutrition. J. Infect. 60(6), 505–507 (2010).
  MedlineGoogle Scholar
• 39. Roveta S, Marchese A, Schito GC. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int. J. Antimicrob. Agents 31(4), 321–328 (2008).
  Medline CASGoogle Scholar
• 40. Luther MK, Arvanitis M, Mylonakis E, Laplante KL. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae. Antimicrob. Agents Chemother. 58(8), 4612–4620 (2014).
  MedlineGoogle Scholar
• 41. Zheng JX, Sun X, Lin ZW et al. In vitro activities of daptomycin combined with fosfomycin or rifampin on planktonic and adherent linezolid-resistant isolates of Enterococcus faecalis. J. Med. Microbiol. 68(3), 493–502 (2019).
  Medline CASGoogle Scholar
• 42. Blanco-Di Matteo A, Garcia-Fernandez N, Aguinaga Pérez A et al. In vivo effectiveness of several antimicrobial locks to eradicate intravascular catheter coagulase-negative staphylococci biofilms. Antimicrob. Agents Chemother. 67(1), e0126422 (2023).
  MedlineGoogle Scholar
• 43. Raad Ii, Hanna HA, Boktour M et al. Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrob. Agents Chemother. 49(12), 5046–5050 (2005).
  Medline CASGoogle Scholar
• 44. Sutrave S, Kikhney J, Schmidt J et al. Effect of daptomycin and vancomycin on Staphylococcus epidermidis biofilms: an in vitro assessment using fluorescence in situ hybridization. PLOS ONE 14(8), e0221786 (2019).
  Medline CASGoogle Scholar
• 45. Olson ME, Slater SR, Rupp ME, Fey PD. Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm. J. Antimicrob. Chemother. 65(10), 2164–2171 (2010).
  Medline CASGoogle Scholar
• 46. Hall Snyder AD, Vidaillac C, Rose W, McRoberts JP, Rybak MJ. Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK/PD model of bacterial biofilm. Infect. Dis. Ther. 4(1), 51–65 (2014).
  MedlineGoogle Scholar
• 47. Ortega R, Salmerón-García A, Cabeza J, Capitán-Vallvey LF, Navas N. Stability of daptomycin 5 mg/ml and heparin sodium 100 units/ml combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20 °C. Am. J. Health Syst. Pharm. 71(11), 956–959 (2014).
  Medline CASGoogle Scholar
• 48. Kaneko H, Nakaminami H, Ozawa K, Wajima T, Noguchi N. In vitro anti-biofilm effect of anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents against the USA300 clone. J. Glob. Antimicrob. Resist. 24, 63–71 (2021).
  Medline CASGoogle Scholar
• 49. Rukayadi Y, Han S, Yong D, Hwang JK. In vitro antibacterial activity of panduratin A against enterococci clinical isolates. Biol. Pharm. Bull. 33(9), 1489–1493 (2010).
  Medline CASGoogle Scholar
• 50. Neudorfer K, Schmidt-Malan SM, Patel R. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagn. Microbiol. Infect. Dis. 90(1), 58–63 (2018).
  Medline CASGoogle Scholar
• 51. Meredith EM, Harven LT, Berti AD. Antimicrobial efficacy against antibiotic-tolerant Staphylococcus aureus depends on the mechanism of antibiotic tolerance. Antibiotics (Basel) 11(12), 1–7 (2022).
  Google Scholar
• 52. Ledger EVK, Mesnage S, Edwards AM. Human serum triggers antibiotic tolerance in Staphylococcus aureus. Nat. Commun. 13(1), 2041 (2022).
  Medline CASGoogle Scholar
• 53. Ledger EVK, Edwards AM. Growth arrest of Staphylococcus aureus induces daptomycin tolerance via cell wall remodelling. mBio 14 (.1), e0355822 (.2023).
  MedlineGoogle Scholar
• 54. Ranganathan N, Johnson R, Edwards AM. The general stress response of Staphylococcus aureus promotes tolerance of antibiotics and survival in whole human blood. Microbiology (Reading) 166(11), 1088–1094 (2020).
  MedlineGoogle Scholar
• 55. Sulaiman JE, Long L, Qian PY, Lam H. Proteome profiling of evolved methicillin-resistant Staphylococcus aureus strains with distinct daptomycin tolerance and resistance phenotypes. Front. Microbiol. 13, doi: 10.3389/fmicb.2022.970146 (.2022) (Online).
  Google Scholar
• 56. Miller CR, Monk JM, Szubin R, Berti AD. Rapid resistance development to three antistaphylococcal therapies in antibiotic-tolerant Staphylococcus aureus bacteremia. PLoS ONE 16(10), e0258592 (2021).
  Medline CASGoogle Scholar
• 57. Sulaiman JE, Lam H. Novel daptomycin tolerance and resistance mutations in methicillin-resistant Staphylococcus aureus from adaptive laboratory evolution. mSphere 6(5), e0069221 (2021).
  MedlineGoogle Scholar
• 58. Berti AD, Shukla N, Rottier AD et al. Daptomycin selects for genetic and phenotypic adaptations leading to antibiotic tolerance in MRSA. J. Antimicrob. Chemother. 73(8), 2030–2033 (2018).
  Medline CASGoogle Scholar
• 59. Mechler L, Bonetti EJ, Reichert S et al. Daptomycin tolerance in the Staphylococcus aureus pitA6 mutant is due to upregulation of the dlt operon. Antimicrob. Agents Chemother. 60(5), 2684–2691 (2016).
  Medline CASGoogle Scholar
• 60. Mechler L, Herbig A, Paprotka K, Fraunholz M, Nieselt K, Bertram R. A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus. Antimicrob. Agents Chemother. 59(9), 5366–5376 (2015).
  Medline CASGoogle Scholar
• 61. Tickle ARH, Ledger EVK, Edwards AM. Human serum induces daptomycin tolerance in Enterococcus faecalis and viridans group streptococci. Microbiology (Reading) 168(12), doi: 10.1099/mic.0.001282 (2022) (Online).
  MedlineGoogle Scholar
• 62. Brewer W, Harrison J, Saito HE, Fozo EM. Induction of daptomycin tolerance in Enterococcus faecalis by fatty acid combinations. Appl. Environ. Microbiol. 86(20), e01178-20 (2020).
  MedlineGoogle Scholar
• 63. Yılmaz H, Mutlu Yılmaz E, Esen S, Sünbül M, Leblebicioğlu H. [Treatment of hemodialysis catheter-associated bacteremia due to methicillin-resistant Staphylococcus aureus by daptomycin lock method]. Mikrobiyol. Bul. 46(3), 470–474 (2012).
  MedlineGoogle Scholar
• 64. Güler Ö BS, Taşçıoğlu D, Çağatay A, Özsüt H, Eraksoy H. Comparison of in vitro effects of different antibiotic-heparin catheter lock solutions on methicillin-resistant Staphylococcus aureus isolates in biofilm. Klimik Magazine 29(1), 25–28 (2019).
  Google Scholar
• 65. Cubicin: EPAR –product information (2023). https://www.ema.europa.eu/en/documents/product-information/cubicin-epar-product-information_en.pdf
  Google Scholar
• 66. Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin. Microbiol. Rev. 26(4), 759–780 (2013).
  Medline CASGoogle Scholar
• 67. Raad I, Chaftari AM, Zakhour R et al. Successful salvage of central venous catheters in patients with catheter-related or central line-associated bloodstream infections by using a catheter lock solution consisting of minocycline, EDTA, and 25% ethanol. Antimicrob. Agents Chemother. 60(6), 3426–3432 (2016).
  Medline CASGoogle Scholar
• 68. Hachem R, Kanj S, Hamerschlak N et al. International experience with minocycline, EDTA and ethanol lock for salvaging of central line associated bloodstream infections. Expert Rev. Med. Devices 15(6), 461–466 (2018).
  Medline CASGoogle Scholar
• 69. van den Bosch CH, Jeremiasse B, van der Bruggen JT et al. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. J. Hosp. Infect. 123, 143–155 (2022).
  MedlineGoogle Scholar
• 70. Brescia F, Pittiruti M, Scoppettuolo G et al. Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients. J. Vasc. Access 24(1), 87–91 (2023).
  MedlineGoogle Scholar
• 71. Mermel LA, Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. J. Antimicrob. Chemother. 69(10), 2611–2619 (2014).
  Medline CASGoogle Scholar
• 72. Zhang J, Wang B, Wang J, Yang Q. Ethanol locks for the prevention of catheter-related infection in patients with central venous catheter: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE 14(9), e0222408 (2019).
  Medline CASGoogle Scholar
• 73. El Haddad L, Hanson BM, Arias CA et al. Emergence and transmission of daptomycin and vancomycin-resistant enterococci between patients and hospital rooms. Clin. Infect. Dis. 73(12), 2306–2313 (2021).
  MedlineGoogle Scholar
• 74. Muff S, Tabah A, Que YA et al. Short-course versus long-course systemic antibiotic treatment for uncomplicated intravascular catheter-related bloodstream infections due to Gram-negative bacteria, enterococci or coagulase-negative staphylococci: a systematic review. Infect. Dis. Ther. 10(3), 1591–1605 (2021).
  MedlineGoogle Scholar
• 75. Hebeisen UP, Atkinson A, Marschall J, Buetti N. Catheter-related bloodstream infections with coagulase-negative staphylococci: are antibiotics necessary if the catheter is removed? Antimicrob. Resist. Infect. Control 8, 21 (2019).
  MedlineGoogle Scholar